
Overview
Stenocoat is a company that specializes in developing customized coatings for medical devices, including lubricious, drug-eluting, antibacterial, hydrophilic, and biocompatible coatings. They focus on urological devices such as catheters and stents, as well as cardiological stents, providing a complete R&D process from design to production and testing. Their services include adapting production lines for coating processes and conducting preclinical studies to evaluate functionality and safety.
Financials
Revenue history (in k)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 83 days for 2021).
- 202518/07/2026
- 202424/06/2025
- 202327/05/2024
- 202230/06/2023
- 202106/10/2022
- 202015/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Coatings for medical devices
- Lubricious coatings
- Drug-eluting coatings
- Antibacterial coatings
- Biocompatible coatings
- Coating technology development
Websites
- stenocoat.comSTENOCOAT – powłoki do wyrobów medycznychWordPress 7.1ElementorYoast SEONginx
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Tomasz Adam Ciach age 61 | 50 | $675.31 | 50% |
Kamil Michał Kopeć age 39 | 50 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Feb 5, 2025 | Aid for research and development projects: industrial research | $102K$101,979 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 22, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Pharmaxi Poland sp. z o.o. | $152,292.34 | pharmaxi.com.ua | ||
| Medesto sp. z o.o. | $120,911.45 | medesto.com.pl | ||
| CBK Med Clinic sp. z o.o. | $91,889.00 | cbkmedclinic.pl | ||
| Cobant sp. z o.o. sp. k. | $39,911.08 | cobant.eu | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| Exomedis sp. z o.o. | $26,633.41 | exomedis.com | ||
| Bonereg sp. z o.o. | $25,113.01 | bonereg.com | ||
| Nanovelos S.A. | $24,842.03 | nanovelos.com | ||
| WEA Techlab sp. z o.o. | $23,105.12 | weatechlab.com | ||
| Poltiss sp. z o.o. | $3,843.72 | poltiss.com |
Change history
| Date | Event | |
|---|---|---|
| 2020-09-23 | Address change (Ul. Sienna 83/502, 00-815, Warszawa → Ul. Symboliczna 3/92, 01-252, Warszawa) | |
| 2020-01-23 | Entered in the register |
FAQ
Last updated: 2026-07-18
